Empirical severity benchmarks for obsessive‐compulsive disorder across the lifespan

Abstract

315 With the pandemic continuing to evolve, it will be critical to keep on answering key questions about the role of SSRIs in the treatment of acute COVID-19 illness. What is the best dose and timing of fluvoxamine, and how effective is it in combination with other treatments against COVID-19 (such as monoclonal antibodies)? Is fluoxetine, which has lower S1R affinity compared to fluvoxamine but has shown promise in preclinical and observational studies, also an effective treatment, considering that it is more widely available and easier to use? And what are the best treatments for neuropsychiatric manifestations of long COVID, and in which patients? Given that many psychotropics are now appreciated to have widespread molecular, cellular and physiological effects, including anti-inflammatory, neuroprotective and cardioprotective, and antiproliferative, we can expect that lessons learned in testing these medications for COVID-19 will be important for other drug repurposing efforts, ranging from infectious and inflammatory diseases, to neurodegenerative diseases such as Alzheimer’s disease, and cancer. Eric J. Lenze, Angela M. Reiersen, Paramala J. Santosh Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA; Department of Child and Adolescent Psychiatry, King’s College London, London, UK